Inflammatory Bowel Disease: What is New?

This article reviews a selection of 50 papers on inflammatory bowel disease published between April 2002 and August 2003. The new information and progress summarized here includes: the role of bacteria, their interaction with CARD15/NOD2 gene products and the modulating effects of probiotics; new imaging techniques, such as wireless capsule endoscopy and chromoendoscopy for detecting dysplasia, and fecal markers. It has not been possible to review every aspect of treatment, and the focus here is on factors capable of predicting the efficacy and tolerance of infliximab and new treatments, including natalizumab, thalidomide, cyclophosphamide and 6-thioguanine.

References

• 1 Bonen D K, Ogura Y, Nicolae D L. et al . Crohn’s disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan.  Gastroenterology. 2003;  124 140-146
• 2 Inohara N, Ogura Y, Fontalba A. et al . Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn’s disease.  J Biol Chem. 2003;  278 5509-5512
• 3 Lala S, Ogura Y, Osborne C. et al . Crohn’s disease and the NOD2 gene: a role for Paneth cells.  Gastroenterology. 2003;  125 47-57
• 4 Fellermann K, Wehkamp J, Herrlinger K R, Stange E F. Crohn’s disease: a defensin deficiency syndrome?.  Eur J Gastroenterol Hepatol. 2003;  15 627-634
• 5 Seksik P, Rigottier-Gois L, Gramet G. et al . Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon.  Gut. 2003;  52 237-242
• 6 Borruel N, Casellas F, Antolin M. et al . Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa.  Am J Gastroenterol. 2003;  98 865-870
• 7 Gionchetti P, Rizzello F, Helwig U. et al . Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.  Gastroenterology. 2003;  124 1202-1209
• 8 Prantera C, Scribano M L, Falasco G. et al . Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG.  Gut. 2002;  51 405-409
• 9 Borody T J, Warren E F, Leis S. et al . Treatment of ulcerative colitis using fecal bacteriotherapy.  J Clin Gastroenterol. 2003;  37 42-47
• 10 Cosnes J, Carbonnel F, Beaugerie L. et al . Effects of appendicectomy on the course of ulcerative colitis.  Gut. 2002;  51 803-807
• 11 Jess T, Winther K V, Munkholm P. et al . Mortality and causes of death in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark.  Gastroenterology. 2002;  122 1808-1814
• 12 Ludeman L, Shepherd N A. What is diverticular colitis?.  Pathology. 2002;  34 568-572
• 13 Spiller R C. Postinfectious irritable bowel syndrome.  Gastroenterology. 2003;  124 1662-1671
• 14 Nahon S, Bouhnik Y, Lavergne-Slove A. et al . Colonoscopy accurately predicts the anatomical severity of colonic Crohn’s disease attacks: correlation with findings from colectomy specimens.  Am J Gastroenterol. 2002;  97 3102-3107
• 15 Brooker J C, Beckett C G, Saunders B P, Benson M J. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn’s strictures may improve the outcome: a retrospective case series.  Endoscopy. 2003;  35 333-337
• 16 Herrerias J M, Caunedo A, Rodriguez-Tellez M. et al . Capsule endoscopy in patients with suspected Crohn’s disease and negative endoscopy.  Endoscopy. 2003;  35 564-568
• 17 Eliakim R, Fischer D, Suissa A. et al . Wireless capsule video endoscopy is a superior diagnostic tool in comparison to barium follow-through and computerized tomography in patients with suspected Crohn’s disease.  Eur J Gastroenterol Hepatol. 2003;  15 363-367
• 18 Messmann H, Endlicher E, Freunek G. et al . Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative colitis using systemic or local 5-aminolaevulinic acid sensitisation.  Gut. 2003;  52 1003-1007
• 19 Kiesslich R, Fritsch J, Holtmann M. et al . Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.  Gastroenterology. 2003;  124 880-888
• 20 Chen R, Rabinovitch P S, Crispin D A. et al . DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free.  Am J Pathol. 2003;  162 665-672
• 21 Stahlberg D, Veress B, Tribukait B, Broome U. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study.  Dis Colon Rectum. 2003;  46 770-778
• 22 Bernstein C N, Eaden J, Steinhart A H. et al . Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.  Inflamm Bowel Dis. 2002;  8 356-361
• 23 Pardi D S, Loftus E V Jr, Kremers W K. et al . Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.  Gastroenterology. 2003;  124 889-893
• 24 Laghi A, Borrelli O, Paolantonio P. et al . Contrast enhanced magnetic resonance imaging of the terminal ileum in children with Crohn’s disease.  Gut. 2003;  52 393-397
• 25 Neurath M F, Vehling D, Schunk K. et al . Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies.  Am J Gastroenterol. 2002;  97 1978-1985
• 26 Van Assche G, Vanbeckevoort D, Bielen D. et al . Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease.  Am J Gastroenterol. 2003;  98 332-339
• 27 Lee S S, Ha H K, Yang S K. et al . CT of prominent pericolic or perienteric vasculature in patients with Crohn’s disease: correlation with clinical disease activity and findings on barium studies.  AJR Am J Roentgenol. 2002;  179 1029-1036
• 28 Kane S V, Sandborn W J, Rufo P A. et al . Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.  Am J Gastroenterol. 2003;  98 1309-1314
• 29 Thjodleifsson B, Sigthorsson G, Cariglia N. et al . Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives?.  Gastroenterology. 2003;  124 1728-1737
• 30 Loftus E V Jr, Crowson C S, Sandborn W J. et al . Long-term fracture risk in patients with Crohn’s disease: a population-based study in Olmsted County, Minnesota.  Gastroenterology. 2002;  123 468-475
• 31 Klaus J, Armbrecht G, Steinkamp M. et al . High prevalence of osteoporotic vertebral fractures in patients with Crohn’s disease.  Gut. 2002;  51 654-658
• 32 von Tirpitz C, Klaus J, Steinkamp M. et al . Therapy of osteoporosis in patients with Crohn’s disease: a randomized study comparing sodium fluoride and ibandronate.  Aliment Pharmacol Ther. 2003;  17 807-816
• 33 De Oca J, Sanchez-Santos R, Rague J M. et al . Long-term results of ileal pouch-anal anastomosis in Crohn’s disease.  Inflamm Bowel Dis. 2003;  9 171-175
• 34 Gramlich T, Delaney C P, Lynch A C. et al . Pathological subgroups may predict complications but not late failure after ileal pouch-anal anastomosis for indeterminate colitis.  Colorectal Dis. 2003;  5 315-319
• 35 Rudolph W G, Uthoff S M, McAuliffe T L. et al . Indeterminate colitis: the real story.  Dis Colon Rectum. 2002;  45 1528-1534
• 36 Ravid A, Richard C S, Spencer L M. et al . Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative colitis.  Dis Colon Rectum. 2002;  45 1283-1288
• 37 Probert C S, Hearing S D, Schreiber S. et al . Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.  Gut. 2003;  52 998-1002
• 38 Domenech E, Garcia-Planella E, Bernal I. et al . Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis.  Aliment Pharmacol Ther. 2002;  16 2061-2065
• 39 Vernia P, Annese V, Bresci G. et al . Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial.  Eur J Clin Invest. 2003;  33 244-248
• 40 Parsi M A, Achkar J P, Richardson S. et al . Predictors of response to infliximab in patients with Crohn’s disease.  Gastroenterology. 2002;  123 707-713
• 41 Vermeire S, Louis E, Carbonez A. et al . Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease.  Am J Gastroenterol. 2002;  97 2357-2363
• 42 Baert F, Noman M, Vermeire S. et al . Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease.  N Engl J Med. 2003;  348 601-608
• 43 Farrell R J, Alsahli M, Jeen Y T. et al . Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial.  Gastroenterology. 2003;  124 917-924
• 44 Kugathasan S, Levy M B, Saeian K. et al . Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction.  Am J Gastroenterol. 2002;  97 1408-1414
• 45 Sabate J M, Villarejo J, Lemann M. et al . An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn’s disease.  Aliment Pharmacol Ther. 2002;  16 1117-1124
• 46 Ghosh S, Goldin E, Gordon F H. et al . Natalizumab for active Crohn’s disease.  N Engl J Med. 2003;  348 24-32
• 47 Caprilli R, Cottone M, Tonelli F. et al . Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn’s disease: a pragmatic, double-blind, randomized controlled trial.  Aliment Pharmacol Ther. 2003;  17 517-523
• 48 Stallmach A, Wittig B M, Moser C. et al . Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease.  Gut. 2003;  52 377-382
• 49 Bonaz B, Boitard J, Marteau P. et al . Thioguanine in patients with Crohn’s disease intolerant or resistant to azathioprine/mercaptopurine.  Aliment Pharmacol Ther. 2003;  18 401-408
• 50 Dubinsky M C, Vasiliauskas E A, Singh H. et al . 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.  Gastroenterology. 2003;  125 298-303